immunohistochemical study of bone marrow biopsy specimens for the presence of LGLL invasion studies, as well as the study of 4 spleens after splenectomy. SS was diagnosed in 8 out of 18 pts (44.5%) according to ACR 2016 criteria. **Results:** Twelve (66.6%) of 18 pts with RA, neutropenia and splenomegaly were diagnosed with T-LGLL, the patients were divided in 2 groups: FS (6 pts) and RA+T-LGLL (12 pts). Pts with FS debuted with arthritis of small hand joints, extremely rarely with extra-articular manifestations, mainly at a young age (36.5±9.3 years), and developed neutropenia after 10 years of RA. Pts with T-LGLL debuted at a younger age (39±4.5 and 5±7.8 years, respectively), had a longer course of RA before the development of neutropenia (14±3.3 and 5±1.5 years, respectively, p<0.03), and more often had extra-articular manifestations at the onset of the disease. RA activity did not differ between groups and in most cases was characterized by a mild course of articular syndrome. Though the course of the RA+T-LGLL group was characterized by low (50%) and moderate (33%) DAS28- CRP activity and active synovitis in only 41.5% of pts, severe joint deformities (stage III and IV) developed in 58.5% of pts. Pts with T-LGLL showed a higher incidence of hemoptoemegaly (75% and 16.5%, respectively, p=0.02) and more severe neutropenia (p=0.02). The development of severe leucopenia (<1x10^3) and massive hepatoplenomegaly was observed only in pts with T-LGLL, which required splenectomy in 4 cases. SS was more often detected in the FS group than in the RA+T-LGLL group (63.5% and 25%, respectively, p<0.02). **Conclusion:** Clinical and laboratory manifestations of FS and T-LGLL are extremely close, therefore, pts who are diagnosed with FS should be examined to exclude T-LGLL.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.3874

**AB0184**

SCREENING FOR DEPRESSION IN A GROUP OF TUNISIAN PATIENTS WITH RHEUMATOID ARTHRITIS

M. Sellami1, S. Kammoun1, S. Miladi2, A. Fazaa1, L. Souabni1, K. Ouenniche1, S. Kassab1, S. Chekili1, K. Ben Abdelghani1, A. Laatar1.1Mongi Slim Hospital, Rheumatology, Tunis, Tunisia

**Background:** Depression is thought to be common comorbidity in patients with rheumatoid arthritis (RA), which is one of the most frequent chronic inflammatory diseases.

**Objectives:** This study aimed to screen for depression in RA patients, and study its relation to social and clinical parameters, as well as disease activity.

**Methods:** Single-center cross-sectional study, involving patients with RA, according to ACR/EULAR criteria 2010, using the original Beck Depression Inventory (BDI) as a screening tool for depression; measures of 0–9 indicated that a patient was not depressed, 10–18 indicated mild to moderate depression, 19–29 indicated moderate to severe depression and 30–63 indicated severe depression.

**Results:** Sixty-five patients were included (57 F / 8 M). The average age was 55 years [23-73]. The mean duration of the disease was 11.75 years [1-25]. Half of the patients had precarious socioeconomic conditions and no social security. Forty-two percent (83.5%) of patients suffered from depression: mild to moderate in 35.4% of cases, moderate to severe in 21.5% of cases and severe in 7.7% of cases. Depression was significantly associated with precarious socioeconomic conditions (p=0.018). A correlation between the BDI score and the Disease Activity Score (DAS28) as well as the Health Assessment Questionnaire was noted (p = 0.046 and p = 0.02, respectively). There were no statistically significant associations with the other studied data.

**Conclusion:** Depression was frequent among RA patients. Our study suggests that better control of the disease may reduce the incidence of depression within this group of patients.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.1396

**AB0185**

ULTRASOUND IN INFLAMMATORY ARTHRALGIA: SHOULD WE ALWAYS SCAN?

K. López Gloria1, I. Castrejon1, J. C. Nieto González1, J. Rivero1, J. Martínez-Barrio1, B. Serrano-Benavente1, L. Trives Folguera1, J. M. Alvaro-Gracia1, J. Molina Collada1,2Hospital Universitario Gregorio Marañón, Rheumatology, Madrid, Spain

**Background:** Patients with inflammatory arthralgia (IA) are considered to be at increased risk for progression to RA. Ultrasound (US) has shown high sensitivity to detect synovitis compared with physical examination. Thus, US is recommended to identify subclinical synovitis in patients without clinical signs of inflammation.

**Objectives:** To determine the frequency and pattern of US detected active inflammation in patients with IA and investigate factors contributing to predict this outcome.

**Methods:** An US clinic is scheduled in an academic center running twice every week. A retrospective analysis of our US unit cohort during a period of 12 months was undertaken. Patients with RA and no previous diagnosis of inflammatory arthropathies were included for analysis. Inclusion criteria of IA definition included: severe symptoms presenting in the morning, duration of morning stiffness ≥60 min, symptoms predominantly located in MCP joints and absence of clinically detected synovitis by the referral rheumatologist. The following routinely collected variables were included in the analysis: demographics, clinical features and laboratory tests. Patients underwent bilateral US examination of hands and/or feet according to the European League Against Rheumatism (EULAR) guidelines. The presence of synovitis and tenosynovitis was assessed on a semi-quantitative scale (0–3) for Grey Scale(GS)/Power Doppler(PD). Active inflammation was defined as PD synovitis and/or tenosynovitis ≥1 at any location. First, differences between groups were tested using chi-squared/Fisher and Student-t tests in the univariate analysis. Second, multivariable logistic regression models were employed to investigate the association between possible predictive factors of US active inflammation.

**Results:** A total of 110 patients were included in the analysis. Mean age was 53.6±15.6 years, 80 (72.7%) were females, and mean symptoms duration was 11.7±9.9 months (Table 1). A total of 76 (69.1%) patients presented with a polycarticular arthralgia pattern. US active inflammation was present in 38 (34.5%) patients (28.2% showed PD synovitis and 19.1% PD tenosynovitis). Hands were most commonly involved with PD synovitis at wrists in 18.2% and at MCP in 14.5% of patients. For PD synovitis, the flexor MCP 2-5 (4.5%) and 6th extensor tenosynovitis (5.5%) were the most frequent affected locations. Only 9 (8.2%) patients had erosions in hands and/or feet at baseline examination. In the univariate analysis, the higher ESR values, the shorter time from symptoms onset and the presence of ACPA were significantly associated with the presence of US active inflammation (n=1, p<0.05 and p<0.01, respectively). In the multivariate analysis, only ACPA and ESR values were significantly associated with the detection of US active inflammation.

**Conclusion:** US features of active inflammation are found in 1 over 3 patients with IA being PD synovitis the most common finding, especially at the wrists and MCP joints. Higher ESR and ACPA values are significantly associated with the presence of US active inflammation. Thus, we strongly recommend the use of PD US to detect subclinical inflammation in at-risk patients with IA with no sign of inflammation on clinical examination, especially those with high ESR and ACPA values.

**Table 1. Baseline characteristics of patients with IA**

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Smoking</th>
<th>ESR</th>
<th>ACPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>53.6±15.6</td>
<td>57±16.2</td>
<td>51±16.4</td>
<td>0.071</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>80 (72.7%)</td>
<td>26 (68.4%)</td>
<td>54 (75%)</td>
<td>0.461</td>
</tr>
<tr>
<td>Non smoker</td>
<td>45 (51.7%)</td>
<td>12 (44.4%)</td>
<td>33 (55%)</td>
<td>0.412</td>
</tr>
<tr>
<td>Smoker</td>
<td>34 (39.1%)</td>
<td>11 (40.7%)</td>
<td>23 (38.3%)</td>
<td>0.763</td>
</tr>
<tr>
<td>Former smoker</td>
<td>8 (9.2%)</td>
<td>4 (14.8%)</td>
<td>4 (6.7%)</td>
<td>0.176</td>
</tr>
<tr>
<td>Extension</td>
<td>12 (10.9%)</td>
<td>6 (15.8%)</td>
<td>6 (8.3%)</td>
<td>0.176</td>
</tr>
<tr>
<td>Oligosynovitis</td>
<td>22 (20%)</td>
<td>10 (26.3%)</td>
<td>12 (16.7%)</td>
<td>0.035</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td>76 (69.1%)</td>
<td>22 (57.9%)</td>
<td>54 (75%)</td>
<td>0.035</td>
</tr>
<tr>
<td>Time (months)</td>
<td>11.7±9.9</td>
<td>9.1±8.1</td>
<td>13±10.5</td>
<td>0.035</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.3996

**AB0186**

AT WHAT LEVEL SHOULD WE MEASURE INTIMA-MEDIA THICKNESS IN RHEUMATOID ARTHRITIS?

I. Nacef1, H. Ferjani2, H. Riahi3, K. Maatallah2, Y. Mabrouk2, E. Labbene3, D. Kaffef7, W. Hamdi7, M. Bouaziz7, Mohamed Taleb Kassab Institute of Orthopedic Surgery and Traumatology, Rheumatology, Tunis, Tunisia; 7Mohamed